Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

J Jendle, M A Nauck, D R Matthews, A Frid, K Hermansen, M During, M Zdravkovic, Boyd Josef Gimnicher Strauss, A J Garber

Research output: Contribution to journalArticleResearchpeer-review

227 Citations (Scopus)

Abstract

The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D
Original languageEnglish
Pages (from-to)1163 - 1172
Number of pages10
JournalDiabetes, Obesity and Metabolism
Volume11
Issue number12
DOIs
Publication statusPublished - 2009

Cite this